S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
BABA   204.64 (+2.09%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
BABA   204.64 (+2.09%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
BABA   204.64 (+2.09%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
BABA   204.64 (+2.09%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:GEVA - Synageva Biopharma Stock Price, Forecast & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency). Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:GEVA
CUSIP87159A10
Phone+1-781-3579900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive GEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for GEVA and its competitors with MarketBeat's FREE daily newsletter.


Synageva Biopharma (NASDAQ:GEVA) Frequently Asked Questions

What is Synageva Biopharma's stock symbol?

Synageva Biopharma trades on the NASDAQ under the ticker symbol "GEVA."

How were Synageva Biopharma's earnings last quarter?

Synageva Biopharma Corp (NASDAQ:GEVA) posted its quarterly earnings results on Thursday, February, 26th. The biopharmaceutical company reported ($1.73) EPS for the quarter, missing the Zacks' consensus estimate of ($1.71) by $0.02. The biopharmaceutical company earned $1.24 million during the quarter, compared to analyst estimates of $1.25 million. View Synageva Biopharma's Earnings History.

Has Synageva Biopharma been receiving favorable news coverage?

Press coverage about GEVA stock has trended somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Synageva Biopharma earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Synageva Biopharma.

Who are some of Synageva Biopharma's key competitors?

What other stocks do shareholders of Synageva Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synageva Biopharma investors own include AutoZone (AZO), Intuitive Surgical (ISRG), AMERCO (UHAL), Regeneron Pharmaceuticals (Regn), Netflix (NFLX), AT&T (T), Ur-Energy (URG), BioMarin Pharmaceutical (BMRN), Celgene (Celg) and Novavax (NVAX).

How do I buy shares of Synageva Biopharma?

Shares of GEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Synageva Biopharma's official website?

The official website for Synageva Biopharma is http://www.synageva.com/.

How can I contact Synageva Biopharma?

Synageva Biopharma's mailing address is 33 Hayden Ave, LEXINGTON, MA 02421-7972, United States. The biopharmaceutical company can be reached via phone at +1-781-3579900.


MarketBeat Community Rating for Synageva Biopharma (NASDAQ GEVA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  350
MarketBeat's community ratings are surveys of what our community members think about Synageva Biopharma and other stocks. Vote "Outperform" if you believe GEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: Why do commodities matter?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel